The interaction between membrane glycoprotein CD36 and glypican 4 (GPC4) induces proteasome-dependent ubiquitination and degradation of GPC4 in CRC cells, reducing the high addiction of CRC cells to glucose or glycolytic inhibition through mitochondrial reduction, i.e., reducing the expression of glycolytic target genes GLUT1, HK2, PKM2, and LDHA, thereby inhibiting the energy metabolism and growth of tumor cells (149). This evidence concerns the gene GPC4 and neoplasm.